Results 141 to 150 of about 5,124 (246)

Successful removal of a perforating ventricular lead after idarucizumab administration [PDF]

, 2020
Sylwia Sławek-Szmyt, Aleksander Araszkiewicz, Lidia Chmielewska‐Michalak, Zofia Oko‐Sarnowska, Maciej Lesiak, Przemysław Mitkowski   +5 more
openalex   +1 more source

Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study [PDF]

, 2020
Zining Wang, Xia Zhao, Pengkang He, Shuqing Chen, Jie Jiang, Akiko Harada, Steven C. Brooks, Yimin Cui   +7 more
openalex   +1 more source

5PSQ-019 Analysis of the use of idarucizumab in a tertiary hospital

Section 5: Patient safety and quality assurance, 2023
C. Rodríguez-Tenreiro Rodríguez, M. Muñoz Villasur, V. García Jiménez, CL Fernández Laguna, L. Macía Rivas, I. de la Fuente Villaverde, S. Fernández Lastras, M. Eiroa Osoro, L. Oyague López, A. Lozano Blázquez   +9 more
semanticscholar   +1 more source

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence [PDF]

, 2017
Slaven Pikija, L. Sztriha, Johannes Sebastian Mutzenbach, Stefan Golaszewski, Johann Sellner   +4 more
openalex   +1 more source

A Reversal Agent in Time can Save Life- The Role of Idarucizumab in Dabigatran Associated Intracranial Bleed- A Case Report

Journal of Neurology and Experimental Neuroscience, 2023

semanticscholar   +1 more source

Dabigatran Reversal with Idarucizumab

New England Journal of Medicine, 2017
Pollack, Charles V., Reilly, Paul A, Weitz, Jeffrey I   +2 more
openaire   +6 more sources

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

, 2016
Paul Reilly, Joanne van Ryn, Oliver Grottke, Stephan Glund, Joachim Stangier   +4 more
openalex   +1 more source

Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study” [PDF]

, 2016
Stephan Glund, Paul Reilly, Joanne van Ryn, Joachim Stangier   +3 more
openalex   +1 more source

PB0699 Idarucizumab for Dabigatran Reversal: A Systematic Review and Meta-Analysis of Indications and Outcomes

Research and Practice in Thrombosis and Haemostasis, 2023
S. van der Horst, E. Martens, P. D. den Exter, M. Bos, M. Huisman, E. Klok   +5 more
semanticscholar   +1 more source

Specific reversal agents for direct oral anticoagulants in neurosurgical emergencies - a systematic review. [PDF]

Res Pract Thromb Haemost
Zeller L, Rohr J, Brandi G, Globas C, Kaserer A, Greutmann M, Schubert T, Studt JD, Geiling K, Regli L, Germans MR.   +10 more
europepmc   +1 more source